EA201591530A1 - Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции - Google Patents

Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции

Info

Publication number
EA201591530A1
EA201591530A1 EA201591530A EA201591530A EA201591530A1 EA 201591530 A1 EA201591530 A1 EA 201591530A1 EA 201591530 A EA201591530 A EA 201591530A EA 201591530 A EA201591530 A EA 201591530A EA 201591530 A1 EA201591530 A1 EA 201591530A1
Authority
EA
Eurasian Patent Office
Prior art keywords
abeksinostat
producing
pharmaceutical compositions
crystal form
corresponding crystal
Prior art date
Application number
EA201591530A
Other languages
English (en)
Other versions
EA030689B1 (ru
Inventor
Анне Пимон-Гарро
Филипп Летельер
Original Assignee
Фармасайкликс Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармасайкликс Элэлси filed Critical Фармасайкликс Элэлси
Publication of EA201591530A1 publication Critical patent/EA201591530A1/ru
Publication of EA030689B1 publication Critical patent/EA030689B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

Тозилат абексиностата формулы (II)и его кристаллическая форма I, которые характеризуются их рентгеновской порошковой дифрактограммой, рамановским спектром и твердотельным ЯМР-спектромС CP/MAS.
EA201591530A 2013-03-04 2014-03-03 Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции EA030689B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2014/050455 WO2014135776A1 (fr) 2013-03-04 2014-03-03 Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA201591530A1 true EA201591530A1 (ru) 2016-01-29
EA030689B1 EA030689B1 (ru) 2018-09-28

Family

ID=48521256

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591530A EA030689B1 (ru) 2013-03-04 2014-03-03 Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
EA201891023A EA039113B1 (ru) 2013-03-04 2014-03-03 Композиция кристаллической формы i тозилата абексиностата, способ ее получения и применение для лечения рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891023A EA039113B1 (ru) 2013-03-04 2014-03-03 Композиция кристаллической формы i тозилата абексиностата, способ ее получения и применение для лечения рака

Country Status (39)

Country Link
US (3) US9115108B2 (ru)
EP (2) EP3252044A1 (ru)
JP (2) JP6449177B2 (ru)
CN (2) CN109734690B (ru)
AR (1) AR094935A1 (ru)
AU (2) AU2014224456B2 (ru)
BR (1) BR112015021443A2 (ru)
CA (1) CA2903369C (ru)
CL (1) CL2015002488A1 (ru)
CR (1) CR20150456A (ru)
CY (1) CY1119147T1 (ru)
DK (1) DK2964622T3 (ru)
DO (1) DOP2015000215A (ru)
EA (2) EA030689B1 (ru)
ES (1) ES2632471T3 (ru)
FR (1) FR3002733B1 (ru)
GE (1) GEP201706760B (ru)
HK (1) HK1220965A1 (ru)
HR (1) HRP20171041T1 (ru)
HU (1) HUE035299T2 (ru)
IL (1) IL241038B (ru)
JO (1) JO3402B1 (ru)
LT (1) LT2964622T (ru)
MA (1) MA38423B1 (ru)
ME (1) ME02814B (ru)
MX (1) MX355436B (ru)
MY (1) MY192027A (ru)
NI (1) NI201500122A (ru)
PE (1) PE20151591A1 (ru)
PL (1) PL2964622T3 (ru)
PT (1) PT2964622T (ru)
RS (1) RS56224B1 (ru)
SG (1) SG11201506952YA (ru)
SI (1) SI2964622T1 (ru)
TN (1) TN2015000367A1 (ru)
TW (1) TWI506023B (ru)
UA (1) UA118550C2 (ru)
UY (1) UY35356A (ru)
WO (1) WO2014135776A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
CA2888960C (en) 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20170043648A (ko) * 2014-09-03 2017-04-21 파마싸이클릭스 엘엘씨 3-[(디메틸아미노)메틸]-n-｛2-[4-(히드록시카르바모일)페녹시]에틸｝-1-벤조푸란-2-카르복사미드의 신규 염, 관련 결정형, 이의 제조 방법 및 이를 함유하는 약학 조성물
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
EP4351734A1 (en) 2021-06-10 2024-04-17 Teva Pharmaceuticals International GmbH Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
DK1611088T3 (da) * 2003-04-07 2009-10-19 Pharmacyclics Inc Hydroxymater som terapeutiske midler
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2014135776A1 (fr) 2014-09-12
CY1119147T1 (el) 2018-02-14
FR3002733B1 (fr) 2015-08-14
SG11201506952YA (en) 2015-10-29
PE20151591A1 (es) 2015-11-06
DK2964622T3 (en) 2017-07-31
JO3402B1 (ar) 2019-10-20
JP6449177B2 (ja) 2019-01-09
BR112015021443A2 (pt) 2017-07-18
EP3252044A1 (fr) 2017-12-06
JP6720280B2 (ja) 2020-07-08
MY192027A (en) 2022-07-23
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
NZ712380A (en) 2020-10-30
CN109734690B (zh) 2023-08-11
CN105263917A (zh) 2016-01-20
CA2903369A1 (en) 2014-09-12
PT2964622T (pt) 2017-07-13
AU2014224456B2 (en) 2018-01-25
MA38423A1 (fr) 2017-02-28
NI201500122A (es) 2018-10-18
CN109734690A (zh) 2019-05-10
CA2903369C (en) 2021-06-08
HUE035299T2 (en) 2018-05-02
MX355436B (es) 2018-04-18
ME02814B (me) 2018-01-20
AU2014224456A1 (en) 2015-10-08
TN2015000367A1 (fr) 2017-01-03
US20140249215A1 (en) 2014-09-04
CN105263917B (zh) 2018-11-20
AU2014224456A8 (en) 2015-10-22
EP2964622B1 (fr) 2017-04-19
CL2015002488A1 (es) 2016-03-11
TWI506023B (zh) 2015-11-01
HK1220965A1 (zh) 2017-05-19
SI2964622T1 (sl) 2017-10-30
US10150748B2 (en) 2018-12-11
UA118550C2 (uk) 2019-02-11
DOP2015000215A (es) 2015-09-30
MX2015011566A (es) 2016-06-24
GEP201706760B (en) 2017-10-25
EA030689B1 (ru) 2018-09-28
EA039113B1 (ru) 2021-12-06
AR094935A1 (es) 2015-09-09
IL241038B (en) 2019-09-26
US20170313671A1 (en) 2017-11-02
IL241038A0 (en) 2015-11-30
HRP20171041T1 (hr) 2017-10-06
EA201891023A1 (ru) 2019-03-29
EP2964622A1 (fr) 2016-01-13
ES2632471T3 (es) 2017-09-13
US20150315167A1 (en) 2015-11-05
LT2964622T (lt) 2017-08-10
UY35356A (es) 2014-09-30
PL2964622T3 (pl) 2017-10-31
RS56224B1 (sr) 2017-11-30
AU2018202881A1 (en) 2018-05-17
FR3002733A1 (fr) 2014-09-05
MA38423B1 (fr) 2017-10-31
CR20150456A (es) 2015-10-21
JP2016510735A (ja) 2016-04-11
JP2019069955A (ja) 2019-05-09
AU2018202881B2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
EA201591530A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
PH12015502814A1 (en) 4-membered ring carboxamides used as nematicides
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2015014470A (es) Analogos de combretastatina.
UA111334C2 (uk) Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
DOP2017000144A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
EA201791098A1 (ru) Способ синтеза производных бензазепина
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона
UA112146C2 (uk) Спосіб отримання 4,1-бензоксатієпін-3-ону
TN2015000573A1 (en) 4-membered ring carboxamides used as nematicides